Related by context. All words. (Click for frequent words.) 84 Prostate Lung Colorectal 82 Screening Trial 73 Ovarian Cancer Screening 72 Digital Mammographic Imaging 67 European Randomized Study 66 multicenter randomized clinical 66 Trial PCPT 66 Prostate Cancer Prevention 66 PLCO 65 Atherosclerosis MESA 65 CALGB 65 BCIRG 65 Gynecologic Oncology Group 65 CARDIA 64 multicenter phase 64 Screening Trial DMIST 64 ACRIN 64 Sorafenib HCC Assessment 64 number NCT# ClinicalTrials.gov 64 EURIDIS 64 ONTARGET 63 Randomized Phase II 63 prospective observational 63 NCCTG 63 Multi Ethnic Study 63 Women Ischemia Syndrome 63 Intervention Trial GAIT 63 Communities ARIC study 63 NO# [002] 63 Patient Registry 63 REVIVE Diabetes 63 randomized controlled clinical 63 Clinical Antipsychotic Trials 62 LUMINATE 62 PRESEPT 62 multicenter clinical 62 STRIDE PD 62 Multicenter 62 prospective multicentre 62 ongoing Phase IIIb 62 Prospective Randomized 62 placebo controlled Phase III 62 Phase Ib clinical 62 multicenter prospective 62 HCV SPRINT 62 BRIM3 62 HPTN 62 Multicenter AIDS 62 phase IIIb 62 Framingham Offspring Study 62 registrational Phase 62 International Verapamil SR 62 Aggressive Reduction 62 ELCAP 61 Multiethnic Study 61 Platelet Inhibition 61 Intervention Effectiveness 61 Alzheimer Disease Cooperative 61 Randomized Study 61 Heart Failure Trial 61 Combination REOLYSIN R 61 Young Adults CARDIA 61 ENESTnd 61 LUX Lung 61 Trial NLST 61 Cholesterol Levels SPARCL 61 Cardiac Allograft Rejection 61 multicentre randomized 61 Evaluation WISE 61 Radiation Therapy Oncology 61 Oral Fingolimod 61 Phase IIIb clinical 61 Phase #b/#a clinical 61 Study ADCS 61 ENDEAVOR IV 61 longitudinal cohort study 61 fosbretabulin 61 Health Initiative Observational 61 Asthma Intervention 61 SWOG 61 CT Colonography Trial 61 Preclinical Study 61 Multicentre 61 Group RTOG 61 prospective observational cohort 61 REGARDS 61 Randomized Double Blind 61 CLARITY TIMI 60 RTOG 60 CAPRIE 60 HORIZONS AMI trial 60 NSABP B 60 AACR San Antonio 60 PERSEUS clinical program 60 CAMMS# 60 Phase Ib II 60 Multicenter Randomized 60 NSABP 60 phase IIb clinical 60 Pre RELAX AHF 60 Randomized Controlled 60 NABTT 60 Carotid Revascularization Endarterectomy vs. 60 #nd EORTC NCI 60 retrospective cohort 60 designated HVTN 60 Multicenter Automatic Defibrillator Implantation 60 Alpha Tocopherol Beta Carotene 60 Meta analyzes 60 SPIRIT FIRST 60 ExTRACT TIMI 60 EVEREST II 60 evaluating tivozanib 60 relapsed MM 60 CALGB # [002] 60 MEND CABG 60 CTRC AACR San Antonio 60 II Clinical Trial 60 CALERIE 60 multicenter randomized controlled 60 multicenter study 60 Blinatumomab 60 Refractory Angina 60 INSPIRE Trial Phase III 60 Genitourinary Cancers Symposium 60 CYT# potent vascular disrupting 60 placebo controlled clinical 60 Phase 2b Clinical Trial 60 IIa clinical 60 FOLOTYN ® 60 clinical pharmacology studies 60 Phase IIIb study 60 Edge STudy 60 GAMMAGARD 60 Swedish Mammography Cohort 60 Lung Cancer Screening 60 Ocular Hypertension Treatment 60 Pooled Analysis 60 retrospective cohort study 60 RECORD1 59 LibiGel Phase III 59 MEK Inhibitor 59 Baltimore Longitudinal Study 59 longitudinal observational study 59 Colposcopy 59 Outpatient Setting 59 Topline Results 59 BARI 2D 59 IMPROVE HF 59 INTERHEART study 59 Framingham Offspring 59 randomized controlled Phase 59 Nord Trøndelag Health 59 MADIT 59 BSGI MBI 59 substudy 59 Tanespimycin 59 Cervista HPV HR 59 PROSTASCINT R 59 MADIT CRT 59 Phase Ib Clinical Trial 59 sorafenib tablets 59 Ozarelix 59 undergone radical prostatectomy 59 double blinded randomized 59 Bowel Project NSABP 59 Multicenter Phase 59 IASLC 59 Hsp# Inhibitor 59 Clinical Trial Results 59 ABCSG 59 Alzheimer Disease Neuroimaging Initiative 59 Phase IIIb 59 multicentre prospective 59 Lipid Lowering Treatment 59 Cell Transplant 59 Meta Analysis 59 cytologically confirmed 59 EXPLORE Xa 59 Randomized Double blind 59 Intervention Trial 59 Clinical Evaluation 59 intravesical infusion therapy 59 CARDIA study 59 randomized multicenter trial 59 Endovascular Valve Edge 59 pharmacokinetic PK 59 multicenter Phase II 59 NGFN 59 Intervention Effectiveness CATIE 59 Advanced Renal Cell 59 lexidronam injection 59 Prostate AdenoCarcinoma Treatment 59 blinded randomized placebo controlled 59 BRIM2 59 Left Ventricular Dysfunction 59 Curaxin CBLC# 59 See CLINICAL PHARMACOLOGY 59 LungAlert TM 59 PRECiSE 59 DAPT Study 59 ThermoDox ® clinical 59 TG MV 59 Metabolomics 59 Gastric Cancer 59 Arch Surg 59 cardio renal 59 Randomized Phase 59 CAPRISA 59 HeFT 59 Phase Ib clinical trials 59 MGd 59 Spine Patient Outcomes 59 malignant mesothelioma Alfacell 59 Phase 1b clinical trials 58 SEER database 58 Wisconsin Sleep Cohort 58 phase IIb study 58 FASEB J. 58 EchoCRT 58 Controlled Trial 58 Clinical Outcome 58 CHAMPION PCI 58 observational cohort study 58 Hepatocellular Carcinoma 58 dose escalation clinical 58 DMIST 58 Clinical Outcomes Utilizing Revascularization 58 histologically confirmed 58 CTAP# Capsules 58 placebo controlled Phase 58 multicenter Phase 58 Carotid Endarterectomy 58 APPRAISE 58 Prostate Cancer ERSPC 58 Randomized Evaluation 58 multicenter 58 evaluating mipomersen 58 Insulin Resistance Atherosclerosis 58 PRE SURGE 58 Gamma Imaging BSGI 58 ASCO Breast Cancer 58 ASCO GU 58 Tumor Response 58 Adult Stem Cell Therapy 58 RE LY 58 Phase III Clinical Trial 58 HCV RESPOND 2 58 Radiology Imaging Network ACRIN 58 AIR2 Trial 58 Metastatic Prostate Cancer 58 Therapeutics TCT scientific 58 phase IIa clinical 58 postmenopausal osteoporotic women 58 multicenter Phase III 58 Inflammatory Markers 58 Prospective Multicenter 58 YONDELIS 58 Severe Sepsis 58 CARE HF 58 Glucosamine Chondroitin Arthritis 58 specific antigen PSA 58 Stenting Trial CREST 58 Phase III psoriasis 58 AACR #st Annual Meeting 58 Biological Therapy 58 Immunohistochemistry 58 Myocardial Infarction Study 58 Randomized Phase III 58 By JENNIFER LEARN 58 SABCS 58 Nymox NX 58 End Results SEER 58 ongoing Phase 1b 58 Immunotherapeutic 58 Observational Study 58 Chicago Multidisciplinary Symposium 58 Phase III multicenter 58 Phase IIB 58 VADT 58 Deforolimus 58 p# biomarker 58 Randomized Clinical Trial 58 HER2 positive metastatic breast 58 PLCO trial 58 Pivotal Clinical Trial 58 Cancer Biomarkers 58 depsipeptide 58 NOX E# 58 SUCCEED trial 58 Evaluation Program CTEP 58 TRA 2P 58 First Patient Enrolled 58 SPIRIT IV 58 Sequenced Treatment Alternatives 58 Aflibercept 58 randomized Phase III 58 identifier NCT# 58 XIENCE V Stent System 58 prospective nonrandomized 58 Atherosclerosis Risk 58 metastatic HRPC 58 Randomized controlled 58 COSIRA trial 58 Acute Decompensated Heart Failure 58 PRTX 58 TMC# C# 58 multicenter randomized 58 COU AA 58 AIM HIGH 58 Trandolapril 58 APTIMA HPV 58 Prostate Cancer Outcomes 58 TITLE Auctions 58 Postmenopausal Women 58 forodesine 57 J Rheumatol 57 recurrent glioma 57 Renal Cell Carcinoma RCC 57 MEK inhibitor 57 ACUITY trial 57 Phase 2a Clinical Trial 57 RE LY ® 57 Myocet 57 randomized clinical 57 Normative Aging Study 57 BR.# 57 Coronary Artery Calcium 57 Solid Tumors 57 HNRCA 57 ERSPC 57 CombAT 57 NHANES III 57 miRview ™ squamous 57 Metastatic Melanoma 57 TAXUS ATLAS 57 Biomarker Study 57 Dupuytren Disease 57 NCIC CTG 57 multicenter randomized double 57 Diabetes Complications 57 Phase III AFFIRM 57 prospective multicenter 57 Dialysis Outcomes 57 Birth Defects Prevention 57 Pivotal Study 57 Phase 1a clinical 57 prospective longitudinal 57 Coronary Artery Risk 57 kidney urologic 57 pertuzumab 57 NLSY 57 CT Colonography 57 Canadian Multicentre Osteoporosis 57 Long Lesion 57 Septin9 57 TEMSO 57 #:#-# [007] 57 trials RCTs 57 NESARC 57 Relapsing Multiple Sclerosis 57 Cytopathology 57 ADMIRE HF 57 ASCO Annual Meeting 57 multicenter placebo controlled 57 Vaccine Protects Against 57 Phase III randomized 57 NCI Cancer 57 Genetic Markers 57 multicenter trials 57 conducted retrospective cohort 57 National Surgical Adjuvant 57 Phase IIb Clinical Trial 57 AIR CF1 57 prostate cancer CaP 57 Endocrine Society #st 57 multicenter multinational 57 Sapacitabine 57 PARTNER Trial 57 PSMA ADC 57 metastatic castration resistant 57 Cancer Epidemiol Biomarkers Prev 57 TAXUS VI 57 Double Blind Placebo 57 unique alkylating agent 57 ARCALYST ® rilonacept 57 recurrent glioblastoma multiforme 57 prospective observational studies 57 Advanced Neuroendocrine Tumors 57 Antitumor Activity 57 Prolongs Survival 57 EORTC 57 European Sepsis Trial 57 Phase III metastatic melanoma 57 Investigator Initiated 57 novel VDA molecule 57 Study AREDS 57 THAT ARE DIFFICULT TO 57 relapsing remitting MS RRMS 57 PRoFESS 57 HDAC Inhibitor 57 Pivotal Trial 57 Randomized Controlled Trials 57 CIBMTR 57 preclinical efficacy 57 HYVET 57 Secondary efficacy endpoints 57 interferon gamma 1b 57 Cervical Pathology 57 prospective randomized multicenter 57 Placebo Controlled Trial 57 ImmuKnow assay 57 blinded placebo controlled 57 PROactive study 57 Autologous Stem Cell Transplantation 57 Cancer Prevention ATBC 57 phase IIb trial 57 controlled multicenter 57 Phase III placebo controlled 57 observational cohort 57 Amrubicin 57 randomized multicenter 57 Gastrointestinal Oncology 57 AVERROES 57 TIMI Study Group 57 controlled dose escalation 57 GVAX Pancreas Vaccine 57 Preclinical Data 57 EMPOWER ™ 57 rALLy clinical trial 57 Geochimica et Cosmochimica Acta 57 sunitinib malate 57 Pediatric Oncology Branch 57 #F FDG PET 57 Invasive Breast Cancer 57 Prostate Cancer Screening 57 Phase 1b trial 57 Health Examination Survey 57 Birth Cohort 57 Surgical Treatment 57 immunohistochemical 56 EUS FNA 56 www.cancerconsultants.com 56 CATIE AD 56 confirmatory clinical 56 Advaxis Phase 56 Phase III Clinical Trials 56 Digene HPV Test 56 Therapeutic Targets 56 Communities ARIC Study 56 Polyp Prevention Trial 56 multicentre randomized double 56 Rotary VAD 56 recurrent metastatic ovarian cancer 56 CALGB # [001] 56 Pivotal Phase 56 Malignant Melanoma 56 ISPOR 56 Laryngeal Cancer 56 RE LY trial 56 evaluating REVLIMID 56 Arthritis Musculoskeletal 56 INCB# [003] 56 Translational Science Award 56 superficial bladder cancer 56 Sipuleucel T 56 Gynecological Cancer 56 KLRI 56 Phase Ib IIa 56 Chronic Heart Failure 56 Systemic Sclerosis 56 metastatic neuroendocrine tumors 56 Clostridium difficile Infection 56 Phase 2a trial 56 Molecular Genetic 56 Am J Pathol 56 phase IIa 56 oral deforolimus 56 Osteoporotic Fractures 56 Eluting Stent 56 iPrEx study 56 CaPSURE 56 AVOREN 56 pralatrexate injection folate analogue 56 J Clin Endocrinol Metab 56 APEX PD 56 NHGRI Division 56 Celecoxib APC trial 56 cMET 56 randomized blinded 56 castrate resistant prostate cancer 56 NHANES 56 multicentric 56 Ocrelizumab 56 #st Annual Meeting 56 OPT CHF 56 Immune Tolerance Network 56 Infarct 56 randomized controlled multicenter 56 galiximab 56 Clinical Outcomes 56 pan HDAC inhibitor 56 Delcath Phase III 56 fecal immunochemical test 56 Phase Ia 56 ALN HPN 56 multicentre randomized controlled 56 Sentinel Lymph Node 56 AACR IASLC Joint 56 RE MODEL 56 Stent Thrombosis 56 ALN TTR 56 treatment naive genotype 56 Anti Tumor 56 Nephrol Dial Transplant 56 randomized Phase 2b 56 HDL Selective Delipidation 56 Cytometry 56 Colorectal Cancer Screening 56 EDEMA3 56 STRATEGY FOR AN OPEN 56 Diabetic Macular Edema 56 Hospitalized Patients 56 Tumor Microenvironment 56 Marrow Transplant Research 56 Breast Cancer Detection 56 Cohort Study MACS 56 worsening thrombocytopenia 56 Anti Tumor Activity 56 Elagolix 56 Heart Failure Therapies 56 Azedra 56 Initiates Clinical Trial 56 PhG alpha 1 56 BOLDER II 56 HF ACTION 56 Pertuzumab 56 Neoadjuvant 56 bevacizumab Avastin ® 56 Folfox 56 Replication NCS R 56 ICON7 56 Hepatocellular Carcinoma HCC 56 Toxicogenomics 56 Cellular Therapies 56 RECIST Response Evaluation Criteria 56 lorcaserin Phase 56 Colorectal Screening 56 GATTEX ® 56 GELA 56 tolerability pharmacokinetics 56 MERIT ES 56 standard chemotherapy regimen 56 Phase 2a clinical 56 Completes Patient Enrollment 56 Lp PLA 2 56 Phase 2b study 56 ARRY # 56 Phase 2a clinical trials 56 Truvada tablets 56 AVADO 56 Kidney Int 56 ritonavir boosted 56 Cell Signalling 56 plus Copegus R 56 EQUATE OB 56 Non inferiority 56 randomized crossover 56 Aggressive Drug Evaluation 56 Arch Neurol 56 ONTARGET R 56 Nutrition EPIC 56 J Natl Cancer Inst 56 Chronic Lymphocytic Leukemia CLL 56 Outcomes Research ISPOR 56 #:#-# [024] 56 Institute DCRI 56 Golimumab 56 ABSORB trial 56 Colorectal Cancers 56 Randomized Clinical Trials 56 Hormone Receptor Positive 56 PD2i R 56 Nonalcoholic Fatty Liver Disease 56 Pivotal Phase III 56 dietary questionnaires 56 Advanced Heart Failure 56 HealthGrades analyzed 56 ACCORD Eye 56 ToGA 56 ACCOMPLISH 56 Pediatric Diabetes 56 MET amplification 56 Educational Longitudinal Study 56 HIV HCV coinfected 56 dbGaP 56 trial evaluating PRX# 56 ENDEAVOR clinical 56 bevirimat Study 56 Cancers Symposium 56 Ranolazine 56 Phase #/#a trial 56 AIR CF2 56 AVONEX ® 56 Cellular Immunology 56 Cancer Immunotherapy 56 PreCISe 56 Abstract Accepted 56 Immunomedics Announces 56 Multicenter Study 56 ECTRIMS 56 PROPEL 56 congenital toxoplasmosis 56 DDW ® 56 NCIC Clinical Trials 56 Prognostic Value 56 phase Ib 56 CR# vcMMAE 56 underwent radical prostatectomy 56 Bayer HealthCare Onyx Pharmaceuticals 56 CHARISMA trial 56 stage IIIB 56 MEND CABG II 56 Severe Asthma 56 PORxin TM platforms 56 undergoing androgen deprivation 56 miRview ™ mets 56 Clinical Trials Update 56 GetGoal Phase III 56 NCCTG N# 56 Subgroup Analysis 56 Teplizumab 56 NEVO RES 56 RNAi Therapeutic 56 NCT# ClinicalTrials.gov 56 crizotinib PF # 56 SPIRIT III 56 Phase III Pivotal 56 familial amyloidotic polyneuropathy FAP 56 ASPIRE HIGHER 56 randomized controlled clinical trials 56 HCV Protease Inhibitor 56 TransVax TM 55 Study Evaluating 55 Allogeneic 55 Trial Evaluating 55 ascending dose 55 HQK 55 PNH Registry 55 PD2i ® 55 Acute Heart Failure 55 assessing T DM1 55 quadrivalent HPV vaccine 55 EMBO J. 55 Aortic Stenosis 55 refractory prostate cancer 55 placebo controlled multicenter 55 mg BID dose 55 Therapeutic Arthritis 55 ISEL 55 Outcome Sciences 55 Tuberculosis Vaccine 55 DAPT 55 MSI #F 55 AA Amyloidosis 55 Accelerated Partial Breast Irradiation 55 trastuzumab DM1 T DM1 55 Patient Outcomes 55 Hematological 55 ENDEAVOR III 55 evaluating carfilzomib 55 Complicated Skin 55 retrospective observational study 55 #rd Annual CTRC 55 lymphoid malignancies 55 Demonstrates Sustained 55 phase III ACCLAIM 55 Prospective Randomized Trial 55 Exelixis XL# 55 Childhood Asthma 55 treatment naïve genotype 55 Prostate Specific Antigen PSA 55 PEGylated interferon beta 1a 55 refractory chronic lymphocytic 55 CT colonography CTC 55 prospectively defined 55 PROLARIS 55 Chemotherapeutic Agents 55 AERAS-#/Crucell Ad# 55 QLT# 55 Proellex TM 55 Cedars Sinai Maxine Dunitz 55 Netherlands Cohort Study 55 Female Urology 55 genomewide association study 55 Cardiotoxicity 55 alvespimycin 55 PreCISe study 55 Preclinical Efficacy 55 Nilotinib 55 ENGAGE AF TIMI 55 pancreatic adenocarcinoma 55 EOquin TM phase 55 ACOSOG Z# 55 Randomized trials 55 Postmenopausal Hormone Therapy 55 Oncotype DX colon cancer 55 CYPHER Stent 55 Thrombolysis 55 iPrEx 55 Cancer Genetic Markers 55 ACCORD Lipid 55 samarium Sm 55 Hodgkin lymphoma HL 55 ECASS 55 J Clin Oncol 55 Adjuvant Chemotherapy 55 STEALTH C 55 Primary endpoints 55 MORAb 55 TACI Ig 55 Lung Cancer Trial 55 MAGE A3 ASCI 55 placebo controlled randomized 55 Postmenopausal 55 Percutaneous Tibial Nerve Stimulation 55 Research Network EDRN 55 endometriosis ovarian cysts 55 antibody MAb 55 GISSI 55 Metabolic Disease 55 TRANSFORMS 55 ICAEL 55 Uterine Fibroids 55 carotid artery stenting 55 pivotal bioequivalence 55 Phase IIb clinical trials 55 Kidney Disease Education 55 Lung Screening 55 Wactawski Wende 55 INCB# [001] 55 GRNCM1 55 Neoplasia 55 EMPHASIS HF trial 55 pain palliation 55 Progenitor Cells 55 Corus CAD 55 Current Controlled Trials 55 CBLC# 55 AUA Annual Meeting 55 Zenvia Phase III 55 ASM Biodefense 55 GOUT 55 Metabolic Efficiency 55 ACTEMRA TM 55 Digestive Diseases Week 55 HIF PH inhibitors 55 Ophena 55 multicentre 55 Connective Tissue Oncology 55 IMiDs ® compound 55 Recurrent Breast Cancer 55 Investigational Drug 55 pelvic malignancies 55 Pediatric Rheumatology 55 Traficet EN 55 CIN2 + 55 mapatumumab 55 Controlled Study 55 CINtec R 55 Diabetic Retinopathy 55 riociguat 55 Environ Health Perspect 55 J Immunol 55 STICH trial 55 Haptoglobin 55 randomized controlled trial 55 Bucindolol 55 Stenting Trial 55 Bucuvalas Inc. 55 Poster Discussion 55 Bladder Cancer 55 Antibody Therapeutics 55 Rakai Uganda 55 oral FTY# 55 PFO migraine 55 ASCO GI 55 Randomized Double Blind Placebo 55 HGS ETR2 55 EORTC NCI 55 subgroup analyzes 55 Phase IIb Trial 55 Elocalcitol 55 CEQ# 55 thorough QT 55 Androxal TM 55 Arteriosclerosis Thrombosis 55 ORACLE MS 55 clinico pathological 55 WEB OF SCIENCE 55 ZYBRESTAT fosbretabulin 55 IMC #B 55 UroVysion 55 simplex virus 55 HORIZONS AMI 55 MADIT II 55 anti JCV antibodies 55 randomized Phase IIb 55 Combination Treatment 55 CIMZIA TM certolizumab pegol 55 Hospitals Leuven Belgium 55 Phase 2b clinical 55 EOquin TM 55 ID NCT# 55 dyskinesia PD LID 55 Carotid Stenting 55 BRAF mutated 55 RCW Breast Cancer 55 immunocompetent 55 Initiate Phase 55 TransVax ™ 55 Angiographic 55 BCR ABL inhibitor 55 sulodexide 55 PERSEUS 55 Thoracic Oncology 55 infantile colic 55 randomized discontinuation trial 55 Cystectomy 55 GeoVax DNA 55 Clinical Trial Data 55 Molecular Diagnostic 55 Acute Stroke 55 Computed Tomographic 55 VICTOR E1 55 Long Term Efficacy 55 PON1 activity 55 LEUKINE 55 randomized blinded placebo 55 cat dander allergy 55 ALTTO 55 Systematic Treatment 55 urethral bulking agent 55 #:# -# [004] 55 papillary renal cell carcinoma 55 Pulmonary Arterial Hypertension 55 UEGW 55 FOLFOX6 chemotherapy regimen 55 Pharmacokinetic PK 55 Nutrition Examination Surveys NHANES 55 Am J Epidemiol 55 Survivorship Program 55 Vulnerable Plaque 55 DF HCC 55 dosing cohorts 55 Venous Thromboembolism 55 Survey MEPS 55 Sangamo BioSciences Announces 55 Degarelix 55 GATTEX TM 55 Patient Enrollment 55 budesonide foam 55 Unstable Angina 55 Breast Carcinoma 55 Pharmacodynamic 55 Cardiometabolic 55 prospective randomized placebo 55 Hematology Meeting 55 Home Buyer Seller 55 Faslodex 55 Chemoprevention 55 ABSORB clinical 55 Acute Myocardial Infarction 55 KRAS mutation 55 Preclinical Models 55 Proves Effective 55 ThermoDox R 55 Cardiovascular Outcomes 55 Group ECOG 55 mertansine 55 Heart Failure Patients 55 metastatic castrate resistant 55 Cohort Consortium 55 Therapeutic Efficacy 55 Autism Consortium 55 NeuroStar TMS Therapy 55 OncoVEX GM CSF 55 Val HeFT 55 Selective Electrochemical Tumor Ablation 55 Chronic Liver Disease 55 Phase #/#a 55 iBIO Institute 55 resistant hormone refractory 55 Breast Density 55 Breast Surgeons 55 KRAS mutations occur 55 Temsirolimus 55 Cloretazine 55 J Virol 55 evaluating Actimmune 55 Nonclinical 55 Follicular Lymphoma 55 Patient Accrual 55 multigene expression test 55 immunohistochemical staining 55 Ann Rheum Dis 55 Protexia ® 55 prostate cancer mCRPC 55 Alzheimer Disease Genetics 55 de la Santé et 55 clinically localized prostate 55 Ganite ® 55 recurrent metastatic 55 T1DM 55 Septin 9 55 Urodynamics 55 Jonsson Comprehensive Cancer 55 PCAW 55 Initiates Phase III 55 Aggressive Prostate Cancer 55 Endometrial 55 LAB CGRP 54 CCCEH 54 huC# DM4 54 Complications Trial 54 RE SURGE 54 Tissue Repair 54 Clinicaltrials.gov 54 transplantation HSCT 54 blinded randomized 54 REALITY Trial 54 Natural Catastrophe Stress 54 Osteoarthritis Patients 54 EmbraceAC 54 Raloxifene STAR 54 BZA CE 54 COPERNICUS 54 MOTIVATE 54 huN# DM1 54 LHRH receptor positive 54 Virtual Colonoscopy 54 Gastrointestinal Cancers Symposium 54 ErbB2 positive 54 Leukemias 54 STEP BD 54 Statistical Genetics 54 SNT MC# 54 Phase III randomized controlled 54 transthyretin TTR mediated amyloidosis 54 PROactive Study 54 underwent CABG 54 Arch Intern Med 54 LHON 54 receptor tyrosine kinase inhibitor 54 VITAL Trial 54 prospective randomized controlled 54 metastatic colorectal 54 Phase IIb III 54 Proc Am Soc 54 Lung Cancer IASLC 54 Psychiatric Services #:#-#,# 54 SCD HeFT 54 ST Segment Elevation 54 Vevo LAZR system 54 ACS NSQIP 54 Cancer Therapies 54 Hepatitis C Infection 54 HCV NS5B polymerase 54 Renal Cancer 54 PROSTVAC VF 54 Gynecol Oncol 54 AACR Meeting 54 evaluable subjects 54 DNA methylation markers 54 PHX# 54 deCODE AF TM 54 Microplasmin 54 National Emphysema Treatment 54 BioNumerik 54 CLL8 54 NATRECOR R 54 CIMZIA ™ 54 Integrative Graduate Education 54 dose escalation trial 54 LungSign TM 54 Inflammatory Bowel Diseases 54 axitinib 54 adenotonsillectomy 54 MassGeneral Institute 54 metastatic pancreatic 54 R#/MEM # 54 Inflammatory Arthritis 54 trastuzumab emtansine T DM1 54 flurpiridaz F 54 Urologic Cancer 54 HER2 overexpression 54 Diabet Med 54 genotypic 54 Meets Primary Endpoint